Tachyarrhythmias

Cardiovascular
0
Pipeline Programs
2
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
3 programs
Bi-ventricular Implantable Cardioverter DefibrillatorN/A1 trial
Protecta VR-ICDN/A1 trial
Secura ICDN/A1 trial
Active Trials
NCT00526162Completed83Est. Oct 2008
NCT00982397Completed2,770Est. Sep 2013
NCT00526227Completed81Est. Oct 2008
Abbott
AbbottABBOTT PARK, IL
3 programs
OptiSense LeadN/A1 trial
SJ4 connector and RV high voltage SJ4 leadN/A1 trial
SJM ConfirmN/A1 trial
Active Trials
NCT00870324Completed50Est. Sep 2010
NCT00940888Completed1,701Est. Dec 2015
NCT00746564Completed75Est. Jun 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsProtecta VR-ICD
AbbottSJ4 connector and RV high voltage SJ4 lead
AbbottOptiSense Lead
AbbottSJM Confirm
Rhythm PharmaceuticalsSecura ICD
Rhythm PharmaceuticalsBi-ventricular Implantable Cardioverter Defibrillator

Clinical Trials (6)

Total enrollment: 4,760 patients across 6 trials

NCT00982397Rhythm PharmaceuticalsProtecta VR-ICD

Safety and Clinical Performance of the Protecta ICD and CRT-D

Start: Sep 2009Est. completion: Sep 20132,770 patients
N/ACompleted
NCT00940888AbbottSJ4 connector and RV high voltage SJ4 lead

SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients

Start: Jun 2009Est. completion: Dec 20151,701 patients
N/ACompleted
NCT00870324AbbottOptiSense Lead

OptiSense™ Performance in Detecting Atrial Episodes

Start: Mar 2009Est. completion: Sep 201050 patients
N/ACompleted
NCT00746564AbbottSJM Confirm

Study of New Implantable Loop Recorder

Start: Sep 2008Est. completion: Jun 201475 patients
N/ACompleted
NCT00526227Rhythm PharmaceuticalsSecura ICD

SecuraTM ICD Clinical Evaluation Study

Start: Oct 2007Est. completion: Oct 200881 patients
N/ACompleted
NCT00526162Rhythm PharmaceuticalsBi-ventricular Implantable Cardioverter Defibrillator

ConsultaTM CRT-D Clinical Evaluation Study

Start: Oct 2007Est. completion: Oct 200883 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Physician Program Director, Los Angeles

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

J&J MedTech Neurovascular Senior Financial Analyst, R&D

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$79K - $128K/yr

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)